No Data
ec healthcare (02138) fell by 53.70%, now trading at 0.770 yuan, hitting a 52-week low.
As of 11:44, ec healthcare (02138) fell by 53.70% compared to the previous closing price, now at 0.770 yuan, hitting a 52-week low; the volume was 1.881 million shares, with a turnover of 1.4459 million Hong Kong dollars.
Hong Kong Stocks Fluctuate | Ec Healthcare (02138) fell more than 6%, and it is expected that the overall sales in the second quarter will decrease by up to 4%, and will be removed from the Hang Seng Composite Index.
EC Healthcare (02138) fell more than 6%, as of press time, it fell 6.54%, to HKD 1.00, with a turnover of HKD 1.8006 million.
After being removed from the Hang Seng Composite Index, the stocks plummeted collectively. Dingdang Health (09886) fell by 14.55%. CICC is expected to be removed from the Hong Kong Stock Connect.
Kingwu Finance News | Latest quarterly inspection results of Hang Seng Index companies have been released. Some shares that were removed from the Hang Seng Composite Index were under pressure. Dingdong Health (09886) fell by 14.55%, Messrs Medical (02415) by 14.35%, Ningo Media (09857) by 14.15%, Yidian Cloud (02416) by 13.49%, Saint-nor Pharmaceutical (02257) by 13.3%, Alli International Education Leasing (01563) by 10.71%, Silurian Medical Co., Ltd. (01244) by 9%, Chinasouthcity (01668) by 7.26%, EC Healthcare (02138) by 2.
EC Healthcare (02138) has been removed from the Hang Seng Composite SmallCap Index and may be removed from the Hong Kong Stock Connect.
Hang Seng Index Company announced the latest quarterly review results, in which Ec Healthcare (02138) is removed from the Hang Seng Composite SmallCap Index. The change will be implemented after the market closes on September 6, 2024 (Friday) and will take effect on September 9, 2024 (Monday).
EC Healthcare Reveals Q2 Sales Volume Fluctuations
EC Healthcare (02138.HK): The overall sales for the second quarter is no less than 1.04 billion Hong Kong dollars.
EC Healthcare (02138.HK) announced that during the period from April 1, 2024 to June 30, 2024 (the "Quarter"), the Group is expected to record: (i) a total sales volume of no less than HK$1.04 billion, with a year-on-year decline of no more than 4%; (ii) a year-on-year decline of no more than 3% in the sales of medical services provided by the Group; (iii) a year-on-year decline of no more than 4% in the sales of aesthetic medical, beauty and wellness services in Hong Kong and Macao, China by the Group; (iv) a year-on-year decline of no more than 4% in the sales of aesthetic medical, beauty and wellness services in mainland China by the Group.
No Data
